LIV Pharma

LIV Pharma GmbH was a German pharmaceutical company that specialized in the development, marketing, and distribution of tailored generic cytostatics and oncology medications. The company's product portfolio featured essential chemotherapy treatments, including generic formulations of fluorouracil (5-FU), gemcitabine, and epirubicin, which were utilized across various cancer indications such as breast, colorectal, and pancreatic cancers. In addition to product distribution, LIV Pharma engaged in clinical study projects and provided international procurement, quality control, and certification services within the pharmaceutical supply chain. Headquartered in Oberhaching, Germany, with subsequent operations in Reichshof, the company served as a marketing authorization holder in European markets. LIV Pharma GmbH entered liquidation and was officially terminated in January 2022.